Acura Pharmaceuticals sees $2.3M loss in 3Q

PALATINE - Specialty pharmaceutical company Acura Pharmaceuticals reported a net loss of $2.3 million for the third quarter of 2016 as the company continues to invest in developing its line of abuse-resistent drugs.

The quarter net loss of $2.3 million, or 19 cents per diluted share, compares to net loss of $2.6 million or 23 cents per diluted share for the same period in 2015. Revenues for the quarter were $218,000, compared to $210,000 in the third quarter of 2015.

Research and development expenses were $800,000 in the third quarter of 2016, compared to $400,000 for the same period in 2015. Research and development expenses were primarily associated with product candidates utilizing the Company's Limitx and Impede Technologies.

Selling, marketing, general and administrative expenses were $1.3 million in the third quarter of 2016, versus $2 million in the same period last year. Selling and marketing expenses primarily consist of advertising and marketing activities for Nexafed and Nexafed Sinus.

The company reported a net loss of $8.9 million for the nine months ended Sept. 30, or 75 cents per diluted share, compared to net loss of $4.1 million or 39 cents per diluted share for the same period in 2015.